Latest filing published 18 Sept 2025 for Y-mAbs Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Peter P. Pfreundschuh is a declared insider at 6 companies (finance chief); the most frequent names are UroGen Pharma Ltd., Korro Bio, Inc. and Voyager Therapeutics, Inc. Between 14 August 2014 and 16 September 2025, the trades on record add up to 39 filings.
No open-market purchase appears, only 18 sales worth €288k. Besides market trades, the filings include 9 share grants and 10 option exercises.
The newest entry dates from 18 September 2025: a transaction, in Y-mAbs Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations